Medicon Valley Biomedical Newsletter

Active Biotech AB publishes a new scientific paper "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate c...

Astion Pharma A/S has initiated the recruitment of patients with psoriasis for a clinical study with ASF-1075 cream. ASF-1075 is a potent, anti-inflammatory product that has been developed for the tre...

A new study shows that probiotics in the form of BioGaia´s AB Reuteri Drops protects prematurely born infants against infections caused by bacteria and yeast. Hospital stay for the infants was reduced...

Copenhagen Inventor Group, CIG, and Panagene have announced that they have entered an exclusive licence agreement regarding the right to custom synthesis of peptide nucleic acids, PNA. The agreement a...

Shortly after its one year anniversary, the small biotech company Formbion A/S can celebrate its entry into an agreement with the German pharmaceutical giant Schering AG. The coming three years, Formb...

Blood Systems has announced that it will begin implementing Gambro AB's BCT 7-day platelets companywide over the next several months, following a successful trial period in four of its blood centr...

Gambro AB and DaVita Inc. have agreed to an amended and restated Alliance and Product Supply Agreement. This amendment effectively revokes the termination notice which was provided by DaVita in May pr...

Type 1 diabetes is partly hereditary, but which genes give the hereditary risk is only partly known. International researchers including Professor Åke Lernmark from Lund University have now found a ne...

Maxygen APS has initiated a Phase I clinical trial in the United States to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of Maxy-G34, a next generation Granulocyte Col...

NeuroSearch A/S has signed a conditional agreement to acquire A. Carlsson Research AB, one of Sweden's leading biopharmaceutical companies within discovery and development of drugs for the treatme...

The Phase IIb study with tesofensine is referred to as TIPO-1 and will involve 200 patients with a Body Mass Index, BMI, > 30. The patients will be divided into four groups and will be treated over...

For the sixth year in a row, Novozymes A/S has taken the top position in the Dow Jones Sustainability Group Index, DJSI, in the biotech category - both in Europe and globally. The annual review...

Pharmexa A/S's application to start a Phase Ib trial of the vaccine EP1090 in HIV-infected patients has been approved by the relavant US authorities. In this trial EP1090 is tested using a needle-...

Pharmexa A/S has received a broad patent in the United States on GV1003 and has received Notice of Allowance from the European patent authorities, signifying that a European patent will be issued shor...

Symphogen A/S has announced that the European Patent Office has issued European Patent number 1,583,830 titled, "Method for manufacturing recombinant polyclonal proteins". The patent ...

TopoTarget A/S and CuraGen Corp. have announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase, HDA...

TopoTarget A/S and CuraGen Corp. have announced the initiation of a Phase I clinical trial, evaluating the administration of oral PXD101, a small molecyle histone deacetylase, HDAC, inhibitor, in pati...

TopoTarget A/S and CuraGen Corporation have announced that the Southwest Oncology Group, an American clinical trials coorperative group, has just opened a Phase II clinical trial to test the effects o...

With a capital injection from existing shareholders of close to EUR 30 million, Zealand Pharma A/S has gained the financial strength to continue the development of its drugs for heart and cancer patie...